Bausch + Lomb is advancing two ophthalmic pipeline assets, a dry eye combination therapy and an ocular surface pain treatment, into advanced clinical trials. These therapies have a combined estimated peak sales potential exceeding $2 billion, signaling significant future revenue opportunities for the company.
Bausch + Lomb announced the progression of two key ophthalmic therapies into advanced clinical testing. The dry eye combination therapy, despite missing its Day 29 primary endpoint in Phase 2, showed statistically significant improvement at Day 15 and will proceed to Phase 3 with an adjusted endpoint, targeting $700 million in peak sales. The ocular pain asset, BL1332, met its primary endpoint in Phase 1b and is now in Phase 2, with a target of $1.4 billion in peak sales. This news is a significant positive catalyst for BLCO, as it de-risks future revenue streams and provides a clear path for growth beyond 2028, reinforcing the company's long-term outlook and potentially attracting investor interest.